Significantly oversubscribed rights issue in 2cureX AB
Press Releases Regulatory
On May 23, 2019, the subscription period ended in 2cureX AB’s (“2cureX”) rights issue prior to the market launch of IndiTreat®. The interest in the rights issue was significant and the rights issue was subscribed for a total of approximately SEK 60 million (excl. guarantee commitments), corresponding to a subscription rate of approximately 241 percent. Through the rights issue, a total of 2.070.000 shares will be issued and 2cureX will be provided approximately SEK 24,7 million before issue costs. Settlement notes are expected to be sent out today, May 28, 2019. Sedermera Fondkommission is the financial advisor in connection with the rights issue.
CEO Ole Thastrup comments
“We are very grateful for the interest in our rights issue. I would like to thank our existing shareholders for their trust and thank all interested parties who have signed up for the rights issue. We have several exciting years ahead of us and the issue proceeds will enable us to realize our market launch of IndiTreat® in the best possible way. I look with great confidence on 2cureX’s continued journey.”
Subscription and allotment in the rights issue
The rights issue was subscribed to 59.661.020,30 SEK including pre-subscription commitment and excluding guarantee commitments, corresponding to a subscription rate of approximately 241 percent. 2.070.000 new shares are issued and 2cureX is thus provided approximately SEK 24,7 million before issue costs, which are estimated to amount to approximately SEK 3 million. 2.056.108 shares, corresponding to approximately 99,33 percent of the subscribed issue volume, are subscribed by shareholders with the support of subscription rights. Due to the extensive interest, guarantee commitments are not activated. Settlement notes are expected to be sent out today, May 28, 2019. Subscribers who are not allocated shares will not receive settlement notes.
Number of shares and share capital
When the rights issue has been registered with the Swedish Companies Registration Office, the number of shares in 2cureX will amount to 12.420.000 shares and the share capital will amount to SEK 1.242.000,00.
Trading in BTA (Paid-up for shares)
Trading in BTA will take place on Nasdaq Stockholm First North until the Swedish Companies Registration Office has registered the rights issue. This registration is expected to take place in mid-June 2019.
Financial adviser, issuing agent and legal adviser
Sedermera Fondkommission is the financial advisor and issuing agent to 2cureX in connection with the rights issue. Markets & Corporate Law acts as the legal advisor.
For more information about 2cureX:
|Ole Thastrup, Chief Executive Officer|
|Telephone: +45 22 11 53 99|
Telephone: +46 40 615 14 15
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 28th, 2019.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).